Loratadine + Pseudoephedrine


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Allergic rhinitis, Cold and flu
Adult: As extended release preparation containing loratadine 5 mg and pseudoephedrine sulfate 120 mg: 1 tablet bid. As extended release preparation containing loratadine 10 mg and pseudoephedrine sulfate 120 mg: 1 tab once daily.
Child: 6-12 yr: As syrup containing loratadine 5 mg and pseudoephedrine 60 mg (per 5 ml): ≤30 kg: 2.5 ml bid; >30 kg: 5 ml bid.
Hepatic Impairment
Severe: Initial dose of 1 tab (containing loratadine 5 mg and pseudoephedrine sulfate 120 mg) daily or ½ the usual syrup dose.
Cách dùng
Extended-Release: May be taken with or without food. Swallow whole, do not break, chew or dissolve.
Chống chỉ định
Lactation. Narrow angle glaucoma, urinary retention, severe hypertension, severe coronary artery disease and hyperthyroidism. Patients on MAOI therapy or within 14 days of discontinuing MAOI.
Thận trọng
Glaucoma, increased intraocular pressure, stenosing peptic ulcer and pyloroduodenal obstruction, prostatic hypertrophy, bladder neck obstruction, CV disease, DM, severe liver impairment. Not recommended for use in pregnancy. Elderly. Tablets to be swallowed whole and patients should be instructed not to break, chew, or dissolve such tablets.
Phản ứng phụ
Insomnia, dry mouth, headache, nervousness, epistaxis, pharyngitis, dizziness, fatigue, tachycardia, postural hypotension, transient abnormal hepatic function, urinary retention, CNS stimulation, excitability.
Quá liều
Symptoms: CNS depression (sedation, apnoea, decreased mental alertness, cyanosis, coma, CV collapse), CNS stimulation (insomnia, hallucination, convulsions) and even death. Management: Induce emesis, followed by supportive and symptomatic treatment.
Tương tác
Loratadine: Increased loratadine levels with ritonavir, amprenavir; increased loratadine levels with erythromycin, cimetidine and ketoconazole without evidence of clinical significance or toxicity; may block effects of betahistine. Pseudoephedrine: Increased adverse effects (e.g. somnolence, agitation) with atomoxetine; increased BP or heart rate with sibutramine.
Potentially Fatal: Pseudoephedrine: Increased risk of psychosis with bromocriptine; increased risk of fatal hypertensive crisis with MAOI, avoid concurrent use during and for 2 wk after stopping the MAOI; increased BP with linezolid and selegiline.
Lab Interference
Reactions to skin testing procedures may be reduced, antihistamines should be discontinued 48 hr before procedure.
Tác dụng
Description: Loratadine is a long-acting, non-sedating antihistamine with little antimuscarinic activity. Pseudoephedrine, a vasoconstrictor, acts on the α-receptors and produces a decongestant effect by shrinking congested mucosa in the upper respiratory areas.
Onset: Nasal decongestion: 30 minutes.
Duration: Nasal decongestion: 8 hr (60 mg pseudoephedrine) and 12 hr (120 mg pseudoephedrine in extended release preparations).
Pharmacokinetics:
Absorption: Loratadine: Absorbed rapidly from GI tract, peak plasma concentrations reached in about 1 hr, bioavailability increased and time to peak plasma concentrations delayed when taken with food.
Distribution: Loratadine: 98% bound to plasma proteins; desloratadine 73-76% bound to plasma proteins; loratadine and its metabolites enters into breast milk, but do not to cross the blood-brain barrier significantly. Pseudoephedrine: May distribute into milk, crosses placenta and into CSF.
Metabolism: Loratadine: Undergoes extensive metabolism by cytochrome P450 isoenzymes CYP3A4 and CYP2D6; its major metabolite desloratadine has potent antihistaminic activity; elimination half-lives 8.4 hr (loratadine), 28 hr (desloratadine).
Excretion: Loratadine: Excreted equally in the urine and faeces, mainly in the form of metabolites. Pseudoephedrine: Undergoes incomplete metabolism in the liver by N-demethylation to inactive metabolite; excreted in urine with 55-75% of dose excreted unchanged.
Bảo quản
Store below 25°C.
Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Loratadine + Pseudoephedrine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Amerhino
  • Clarinase Repetabs
  • Lorafed
  • Loratin-D sinus
  • Lormeg-D
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in